Greenwich LifeSciences Secures European Approval for Commercially Manufactured GP2 in FLAMINGO-01 Trial — Greenwich LifeSciences, Inc.

Event summary

European Medicines Agency (EMA) approved the use of commercially manufactured GP2 in the FLAMINGO-01 Phase III trial, aligning with prior FDA approval.
All US and European clinical sites (170-180 total) will now use the same commercially manufactured GP2 lot.
Over 1,300 patients have been screened for FLAMINGO-01, with preliminary data showing a 70-80% reduction in recurrence rates in the non-HLA-A*02 arm.
GP2's baseline immune response suggests it may be a natural antigen, with statistically significant increases in delayed-type-hypersensitivity (DTH) and injection site reactions (ISR) post-treatment.

The big picture

Greenwich LifeSciences' EMA approval for commercially manufactured GP2 marks a critical milestone in its Phase III FLAMINGO-01 trial, which aims to prevent breast cancer recurrences. The alignment of European and US regulatory approvals streamlines global trial operations, while preliminary data suggesting significant recurrence rate reductions positions GLSI-100 as a potential breakthrough immunotherapy. The company's ability to scale manufacturing and secure additional regulatory clearances will be key to its long-term commercial success in the competitive oncology space.

What we're watching

Regulatory Expansion: Whether Greenwich can secure approvals for GP2 use in the UK and Canada, expanding its commercial reach beyond the US and Europe.
Clinical Efficacy: How the preliminary 70-80% recurrence reduction rate in the non-HLA-A*02 arm of FLAMINGO-01 compares to the Phase IIb trial results, which showed an 80% reduction.
Manufacturing Scalability: The pace at which Greenwich can scale commercial manufacturing of GP2 to meet potential global demand if FLAMINGO-01 succeeds.